“Neuropathy” Is a Category, Not a Diagnosis: What Nerve Testing Actually Measures

What this video covers

• What nerve conduction studies and needle electromyography actually measure, and how they differ
• How slowed conduction points to a damaged myelin sheath while reduced amplitude points to axon loss
• How testing separates a pinched nerve root in the spine from carpal tunnel syndrome or a plexus injury
• Why large fiber testing can be completely normal in small fiber neuropathy, and what is used instead
• How diabetes and metabolic disease change the nerve picture, and where glucose control genuinely helps
• When testing is truly indicated, when it is not needed at all, and what the risks of the needle study are
• MEDICAL DISCLAIMER: This content is for educational purposes only and is not medical advice. It does not substitute for professional diagnosis or treatment. Always consult a licensed healthcare provider regarding your condition. Viewing this video does not establish a doctor-patient relationship.

You wake at three in the morning with your hand dead, and you shake it out over the edge of the bed until feeling crawls back in. By autumn your feet burn as though the sheets were packed with hot sand. Somewhere in your chart, someone has written the word neuropathy — and nobody has measured anything.

That word is not a diagnosis. It is a category. This article explains what a nerve conduction study and a needle electromyogram actually measure, why very different problems can feel identical from the inside, what these tests cannot see, and when the evidence says testing is worth doing at all.

“Neuropathy” is a category, not a diagnosis

A nerve root compressed in your lumbar spine, a median nerve strangled at the wrist, a brachial plexus stretched at the shoulder, and small fibers dying quietly in the skin of your feet all produce numbness and burning. Only one of them is helped by an epidural. Each of them has a different natural history, and none of that history can be read off the word in your chart.

Dr. Gurpreet Singh Padda, MD, MBA, MHP, puts the problem plainly: in a fifteen-minute visit, the incentive is to name the symptom and turn the room over. Naming is fast. Measuring is slow. Patients pay the difference in years.

What a nerve conduction study measures: time and size

A peripheral nerve is not a wire. It is a cable of axons, and the large ones are wrapped in myelin — a fatty insulating sleeve laid down by Schwann cells, interrupted at intervals by bare gaps. The impulse does not crawl along the membrane. It jumps, gap to gap. That is why a healthy large fiber conducts fast.

A nerve conduction study (NCS) places a stimulating electrode over the nerve and a recording electrode downstream, delivers a brief electrical pulse, and measures two things directly:

• Time — the latency from stimulus to response, and the conduction velocity across a measured distance.
• Size — the amplitude of the response, sensory and motor.

Those two numbers separate two entirely different diseases.

Slow means insulation

When myelin is damaged, the impulse loses its ability to jump. Latency lengthens, velocity falls, the signal arrives late. That is compressive demyelination, and carpal tunnel syndrome is its textbook example: the median nerve slows precisely across the wrist while that same nerve conducts normally in the forearm above it, and normally again in the palm beyond it.

Small means wiring

When the axon itself dies, timing can look nearly normal, because the surviving fibers still conduct at speed. There are simply fewer of them left to answer, so the amplitude collapses.

The late responses reach where the distal study cannot

The F wave and the H reflex time an impulse sent up to the spinal cord and back. They interrogate the long proximal segment nearest the nerve root — territory the distal study never reaches.

What the needle examination adds

The conduction study tells the physician about the cable. Electromyography (EMG) — the needle examination — tells the physician what the cable is running.

A fine recording needle is placed into selected muscles and the electrical activity is listened to, literally, on a speaker, at rest and during effort. Healthy muscle at rest is electrically silent. Denervated muscle is not: it fires spontaneously, individual fibers discharging with no motor unit left to command them. That is the acoustic signature of denervation.

Two practical consequences follow:

1. Timing matters. Spontaneous activity takes weeks after an injury to appear, which is why a study done too early can be falsely reassuring.
2. EMG is a localizing study, not a screening test. Every muscle is supplied by a specific nerve, from a specific division of the plexus, from a specific nerve root. By sampling muscles that share a root but not a nerve, muscles that share a nerve but not a root, and the paraspinal muscles fed by the root’s posterior branch, the lesion can be placed on the map. Root. Plexus. Peripheral nerve.

Why completely different problems feel identical

Sciatica, diabetic polyneuropathy, and carpal tunnel syndrome overlap almost completely in how they feel to you. They do not overlap at all in where they live.

That is the whole reason the felt symptom cannot be trusted as a location. Burning in the foot at night can come from small fibers dying in the skin, from a root compressed in the lumbar spine, or from a nerve entrapped somewhere along its course in the limb. The sensation tells you something is wrong. It does not tell you where. Measurement does.

It also explains a common and demoralizing experience: an injection aimed at the wrong level or the wrong nerve cannot be expected to work. The injection did not fail. It was never aimed at your problem.

What the standard approach misses

Nothing here is a criticism of the physicians managing neuropathic symptoms with medication. Symptom control has a real role, and for many patients it is a reasonable part of care. What it does not do is answer the question of which nerve is injured, where, and how badly — and no amount of symptom control substitutes for that answer. Do not start, stop, or change any medication without consulting your physician.

But the honest reform is not more testing. It is less testing, aimed better. Electrodiagnostic testing earns its place through diagnostic accuracy, not symptom relief. Before a single electrode touches the skin, there should be a written question the study must answer. If no such question can be written, the study should not be run.

Two established sources anchor that position:

• A joint report of the American Academy of Neurology, the American Association of Electrodiagnostic Medicine, and the American Academy of Physical Medicine and Rehabilitation (England and colleagues, Neurology, 2005) found that symptoms alone have relatively poor diagnostic accuracy for predicting polyneuropathy, that signs on examination predict better, and that the most accurate case definition combines multiple symptoms, multiple signs, and abnormal electrodiagnostic findings.[1]
• The American Diabetes Association position statement (Pop-Busui and colleagues, Diabetes Care, 2017) is blunter still: electrophysiological testing or referral to a neurologist is rarely needed for screening, and is reserved for situations where the clinical features are atypical — motor involvement exceeding sensory, rapid onset, or an asymmetrical presentation — where the diagnosis is unclear, or where a different cause is suspected.[2]

If you have diabetes and classic symmetric burning feet, a clinic that tests you by reflex is performing a ritual, not answering a question.

The limitation that matters most: small fibers are invisible

Nerve conduction studies interrogate large myelinated fibers only. The small fibers that carry burning, temperature, and pain are invisible to them.

So if you have furnace-hot feet at night, normal strength, normal reflexes, and a normal nerve conduction study, you have not been proven healthy. You have been proven to have intact large fibers. Those are not the same statement.

The validated test for small fiber neuropathy is a punch skin biopsy of the distal leg, counting the density of intraepidermal nerve fibers — the joint European Federation of Neurological Societies and Peripheral Nerve Society guideline (Lauria and colleagues, European Journal of Neurology, 2010).[3] That is an established diagnostic technique, distinct from and complementary to nerve conduction testing.

What this means for your evaluation

If you are considering testing, three things are worth understanding before you agree to it.

First, the study should have a question. The fuller explanation of electrodiagnostic evaluation is on the electrodiagnostics and peripheral nerve evaluation page. The point of reading it is not to shop for a procedure — it is to arrive able to ask what question your study is meant to answer.

Second, be honest about what testing costs you. Brief electrical pulses, a fine needle, soreness and bruising afterward. Less common risks include bleeding or hematoma; local infection; and, when the needle study must sample chest wall or thoracic paraspinal muscles, a rare risk of pneumothorax. Tell the physician beforehand if you take anticoagulants, have a bleeding disorder, have lymphedema in the limb, or carry an implanted cardiac device. Do not start, stop, or change any medication without consulting your physician — including blood thinners before a needle study.

Third, when the answer is metabolic, no needle placed in your spine will change it. Glycemic control is genuinely disease modifying, and the same ADA statement grades it honestly: a 78% relative risk reduction for distal symmetric polyneuropathy in type 1 diabetes (Grade A evidence), versus a far smaller 5–9% relative risk reduction in type 2 diabetes (Grade B).[2] That asymmetry is real and should shape expectations rather than be smoothed over.

Some adjuncts get discussed in this space — carbohydrate-restricted nutrition, omega-3-derived pro-resolving mediators, red and near-infrared light therapy. These are investigational and unproven for the nerve injury itself. They are not established care, and none of them is a substitute for knowing which nerve is injured.

A composite illustration

The following is a composite — a picture assembled from many patients with this condition, not one person’s chart. It is offered to show how the reasoning works, not as a representative outcome. Individual results vary.

An adult arrives after two years of burning feet and a right foot that catches on stair edges. The chart says diabetic neuropathy; two lumbar epidurals have been done, and neither helped. Examination finds symmetric loss of pinprick and vibration in both feet, which fits the label — but it also finds weakness of ankle dorsiflexion and eversion on one side only. That does not fit, and asymmetry is exactly the atypical feature the ADA guideline says to test.[2]

Testing shows reduced sensory amplitudes in both legs: axon loss, length dependent, consistent with the diagnosis on the chart. Superimposed on it, the peroneal motor response slows sharply across the fibular head and is normal below it, and the needle examination finds denervation only in muscles supplied by that nerve, with the lumbar paraspinals silent. That is not an L5 nerve root. That is a focal entrapment at the knee. The epidurals were aimed at a level that was never the problem.

What follows is unglamorous: treat the entrapment instead of the spine — pressure off the fibular head, a temporary ankle-foot orthosis while the nerve recovers — and go hard at glucose control, because the metabolic neuropathy underneath is still there. None of it is fast. The foot drop improves over months, not weeks, because a regenerating axon moves at its own pace. The burning does not fully leave; it grows quieter across a year as glucose control tightens. That is a real result, not a cure.

If you have been told you have neuropathy and no one has measured a nerve, ask why not.

Frequently asked questions

Key takeaways

• A nerve conduction study measures two things — timing and size. Slow conduction points to damaged myelin insulation; collapsed amplitude points to axon loss. Needle EMG then localizes the lesion to a root, plexus, or peripheral nerve.
• Sciatica, diabetic polyneuropathy, and carpal tunnel feel almost identical but live in different places, which is why an injection aimed at the wrong level cannot be expected to work.
• Testing is justified by diagnostic accuracy, not symptom relief: symptoms alone predict polyneuropathy poorly, signs predict better, and the combination of symptoms, signs, and electrodiagnostic findings is most accurate.[1]
• Nerve conduction studies see only large fibers. A normal study with burning feet does not rule out small fiber neuropathy, for which distal-leg skin biopsy with intraepidermal nerve fiber counting is the validated test.[3]
• If you carry the label “neuropathy” and no nerve has ever been measured — especially if a prior injection did not help, or your findings are asymmetric — that is the conversation to have next.

Medically reviewed by Gurpreet Singh Padda, MD, MBA, MHP — Board Certified in Anesthesiology, Pain Medicine, Interventional Pain Management, Addiction Medicine, and Obesity Medicine. Last reviewed July 2026.

This article is educational and is not a substitute for evaluation, diagnosis, or treatment by a physician. Individual results vary. Do not start, stop, or change any medication without consulting your physician. To be evaluated at the Padda Institute Center for Interventional Pain Management, call (314) 481-5000 or text (314) 886-5902.

References

1. England JD, Gronseth GS, Franklin G, Miller RG, Asbury AK, et al. Distal symmetric polyneuropathy: a definition for clinical research: report of the American Academy of Neurology, the American Association of Electrodiagnostic Medicine, and the American Academy of Physical Medicine and Rehabilitation. Neurology. 2005;64(2):199-207. PMID 1566841410121201000014952232823. PubMed
2. Lauria G, Hsieh ST, Johansson O, Kennedy WR, Leger JM, et al. European Federation of Neurological Societies/Peripheral Nerve Society Guideline on the use of skin biopsy in the diagnosis of small fiber neuropathy. Eur J Neurol. 2010;17(7):903-912, e44-e49. PMID 2064262710111114681331201003023. PubMed
3. Pop-Busui R, Boulton AJM, Feldman EL, Bril V, Freeman R, Malik RA, Sosenko JM, Ziegler D. Diabetic Neuropathy: A Position Statement by the American Diabetes Association. Diabetes Care. 2017;40(1):136-154. PMID 27999003102337162042. PubMed

Dr. Gurpreet Singh Padda, MD, MBA, MHP